The difficulty to diagnose and treat a rare disease: response to
midostaurin in a case of aggressive systemic mastocytosis conditioning
bulky lymphadenopathy
Abstract
Systemic mastocytosis (SM) can be extremely heterogeneous and its
treatment should be highly individualized. We reported a description of
clinical management of an aggressive SM characterized at diagnosis by
multiple organ involvement. The patient underwent to different lines of
treatment, from standard chemotherapy to the novel tyrosine kinase
inhibitor midostaurin.
, 
